In Brief: Cor Therapeutics Integrilin
Executive Summary
Cor Therapeutics Integrilin: FDA's Cardiovascular & Renal Drugs Advisory Committee will consider amended eptifibatide NDA for percutaneous transluminal coronary angioplasty and acute coronary syndromes on Jan. 28. Cor amended its NDA for Integrilin in early October to include results from the Platelet IIb-IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) trial ("The Pink Sheet" Nov. 10, p. 18). The meeting begins at 9:00 a.m. at NIH's Natcher Auditorium in Bethesda, Md...